| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.78 [0.71, 0.86] | | < 1 | | 62% | 16 studies (16/-) | 100.0 % | some concern | critical | moderate | crucial | - |
| deaths (OS) (extension) | 0.68 [0.60, 0.78] | | < 1 | | 50% | 6 studies (6/-) | 100.0 % | some concern | not evaluable | moderate | important | - |
| PFS (extension) | 0.65 [0.48, 0.86] | | < 1 | | 92% | 6 studies (6/-) | 99.9 % | some concern | not evaluable | moderate | important | - |
| progression or deaths (PFS) | 0.69 [0.60, 0.79] | | < 1 | | 85% | 16 studies (16/-) | 100.0 % | some concern | critical | moderate | important | - |
| DOR | 2.27 [1.44, 3.57] | | < 1 | | 0% | 2 studies (2/-) | 0.0 % | some concern | not evaluable | moderate | non important | - |
| objective responses (ORR) | 1.67 [1.32, 2.11] | | > 1 | | 83% | 15 studies (15/-) | 100.0 % | some concern | low | moderate | non important | - |
| objective responses (ORR) (extension) | 2.00 [1.13, 3.54] | | > 1 | | 88% | 5 studies (5/-) | 99.2 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
| AE (any grade) | 0.71 [0.35, 1.43] | | < 1 | | 80% | 8 studies (8/-) | 83.4 % | some concern | serious | moderate | non important | - |
| AE (grade 3-4) | 0.75 [0.50, 1.14] | | < 1 | | 91% | 8 studies (8/-) | 91.2 % | some concern | not evaluable | moderate | non important | - |
| AE leading to death (grade 5) | 1.21 [0.80, 1.82] | | < 1 | | 57% | 8 studies (8/-) | 18.1 % | some concern | serious | moderate | non important | - |
| AE leading to treatment discontinuation (any grade) | 1.23 [0.78, 1.92] | | < 1 | | 85% | 8 studies (8/-) | 18.8 % | some concern | not evaluable | moderate | non important | - |
| AE leading to treatment discontinuation (grade 3-4) | 1.58 [1.08, 2.31] | | < 1 | | 56% | 5 studies (5/-) | 0.9 % | low | not evaluable | high | non important | - |
| SAE (any grade) | 1.42 [0.82, 2.44] | | < 1 | | 84% | 3 studies (3/-) | 10.4 % | some concern | not evaluable | moderate | non important | - |
| STRAE (any grade) | 1.41 [1.01, 1.96] | | < 1 | | 81% | 11 studies (11/-) | 2.2 % | some concern | low | moderate | non important | - |
| STRAE (grade 3-4) | 1.43 [0.99, 2.06] | | < 1 | | 76% | 9 studies (9/-) | 2.8 % | some concern | not evaluable | moderate | non important | - |
| TRAE (any grade) | 0.57 [0.34, 0.95] | | < 1 | | 93% | 12 studies (12/-) | 98.4 % | some concern | critical | moderate | non important | - |
| TRAE (grade 3-4) | 0.66 [0.40, 1.07] | | < 1 | | 95% | 12 studies (12/-) | 95.5 % | some concern | low | moderate | non important | - |
| TRAE leading to death (grade 5) | 1.11 [0.74, 1.67] | | < 1 | | 0% | 11 studies (11/-) | 30.4 % | some concern | low | moderate | non important | - |
| TRAE leading to discontinuation (any grade) | 1.27 [0.81, 1.98] | | < 1 | | 84% | 10 studies (10/-) | 14.7 % | some concern | low | moderate | non important | - |
| TRAE leading to discontinuation (grade 3-4) | 1.87 [1.21, 2.88] | | < 1 | | 73% | 10 studies (10/-) | 0.3 % | some concern | low | moderate | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Acute kidney injury TRAE (grade 3-4) | 4.32 [0.19, 97.73] | | < 1 | | 0% | 1 study (1/-) | 18.2 % | NA | not evaluable | | non important | - |
| Adrenal insufficiency TRAE (grade 3-4) | 2.57 [0.73, 9.04] | | < 1 | | 0% | 6 studies (6/-) | 7.0 % | some concern | not evaluable | moderate | non important | - |
| Alopecia TRAE (grade 3-4) | 0.48 [0.11, 2.13] | | < 1 | | 0% | 6 studies (6/-) | 83.3 % | some concern | serious | moderate | non important | - |
| Anaemia TRAE (grade 3-4) | 0.18 [0.08, 0.41] | | < 1 | | 90% | 11 studies (11/-) | 100.0 % | some concern | critical | moderate | non important | - |
| Arthralgia TRAE (grade 3-4) | 0.98 [0.06, 15.75] | | < 1 | | 0% | 2 studies (2/-) | 50.5 % | some concern | not evaluable | moderate | non important | - |
| Asthenia TRAE (grade 3-4) | 0.49 [0.27, 0.89] | | < 1 | | 18% | 9 studies (9/-) | 99.0 % | some concern | not evaluable | moderate | non important | - |
| Blood creatinine increased TRAE (grade 3-4) | 1.00 [0.13, 7.77] | | < 1 | | 0% | 3 studies (3/-) | 50.1 % | some concern | not evaluable | moderate | non important | - |
| Colitis TRAE (grade 3-4) | 4.54 [1.70, 12.15] | | < 1 | | 0% | 9 studies (9/-) | 0.1 % | some concern | not evaluable | moderate | non important | - |
| Constipation TRAE (grade 3-4) | 0.64 [0.21, 1.90] | | < 1 | | 0% | 11 studies (11/-) | 79.0 % | some concern | critical | moderate | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.82 [0.49, 1.37] | | < 1 | | 8% | 11 studies (11/-) | 77.3 % | some concern | low | moderate | non important | - |
| Diabetes TRAE (grade 3-4) | 2.04 [0.45, 9.27] | | < 1 | | 0% | 5 studies (5/-) | 17.9 % | some concern | serious | moderate | non important | - |
| Diarrhoea TRAE (grade 3-4) | 1.89 [1.18, 3.04] | | < 1 | | 0% | 13 studies (13/-) | 0.4 % | some concern | low | moderate | non important | - |
| Dizziness TRAE (grade 3-4) | 1.05 [0.02, 53.86] | | < 1 | | 0% | 1 study (1/-) | 49.0 % | NA | not evaluable | | non important | - |
| Dysgeusia TRAE (grade 3-4) | 1.00 [0.10, 9.69] | | < 1 | | 0% | 3 studies (3/-) | 49.9 % | some concern | not evaluable | moderate | non important | - |
| Fatigue TRAE (grade 3-4) | 0.98 [0.56, 1.74] | | < 1 | | 49% | 11 studies (11/-) | 52.3 % | some concern | low | moderate | non important | - |
| Febrile neutropenia TRAE (grade 3-4) | 1.88 [1.04, 3.41] | | < 1 | | 0% | 3 studies (3/-) | 1.9 % | some concern | not evaluable | moderate | non important | - |
| Gastrointestinal disorders TRAE (grade 3-4) | 1.19 [0.36, 3.94] | | < 1 | | 0% | 1 study (1/-) | 39.0 % | NA | not evaluable | | non important | - |
| Guillain-Barré syndrome TRAE (grade 3-4) | 1.00 [0.02, 50.55] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 5.23 [1.82, 15.02] | | < 1 | | 0% | 7 studies (7/-) | 0.1 % | some concern | not evaluable | moderate | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 1.11 [0.34, 3.61] | | < 1 | | 0% | 10 studies (10/-) | 43.4 % | some concern | critical | moderate | non important | - |
| Hypophysitis TRAE (grade 3-4) | 1.88 [0.40, 8.89] | | < 1 | | 0% | 5 studies (5/-) | 21.4 % | some concern | serious | moderate | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 1.81 [0.68, 4.80] | | < 1 | | 0% | 13 studies (13/-) | 11.7 % | some concern | critical | moderate | non important | - |
| Increase AST TRAE (grade 3-4) | 1.67 [0.48, 5.82] | | < 1 | | 0% | 4 studies (4/-) | 21.0 % | some concern | not evaluable | moderate | non important | - |
| Increased ALT TRAE (grade 3-4) | 2.02 [0.97, 4.18] | | < 1 | | 0% | 6 studies (6/-) | 3.0 % | some concern | not evaluable | moderate | non important | - |
| Increased lacrimation (TRAE grade 3-4) | 1.05 [0.02, 53.86] | | < 1 | | 0% | 1 study (1/-) | 49.0 % | NA | not evaluable | | non important | - |
| Increased lipase level TRAE (grade 3-4) | 7.55 [2.24, 25.47] | | < 1 | | 0% | 1 study (1/-) | 0.1 % | NA | not evaluable | | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 0.55 [0.15, 2.03] | | < 1 | | 0% | 6 studies (6/-) | 81.4 % | some concern | serious | moderate | non important | - |
| Leucopenia TRAE (grade 3-4) | 0.35 [0.04, 2.78] | | < 1 | | 69% | 4 studies (4/-) | 83.9 % | some concern | not evaluable | moderate | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 3.26 [0.66, 16.22] | | < 1 | | 0% | 3 studies (3/-) | 7.5 % | some concern | not evaluable | moderate | non important | - |
| Mucosal inflammation TRAE (grade 3-4) | 0.98 [0.02, 49.83] | | < 1 | | 0% | 1 study (1/-) | 50.3 % | NA | not evaluable | | non important | - |
| Myalgia TRAE (grade 3-4) | 1.46 [0.11, 19.02] | | < 1 | | 0% | 2 studies (2/-) | 38.8 % | some concern | not evaluable | moderate | non important | - |
| Myocarditis TRAE (grade 3-4) | 1.94 [0.06, 57.80] | | < 1 | | 0% | 1 study (1/-) | 35.4 % | NA | not evaluable | | non important | - |
| Myositis TRAE (grade 3-4) | 0.79 [0.08, 7.57] | | < 1 | | 0% | 3 studies (3/-) | 58.2 % | some concern | not evaluable | moderate | non important | - |
| Nausea TRAE (grade 3-4) | 0.55 [0.25, 1.19] | | < 1 | | 39% | 11 studies (11/-) | 93.6 % | some concern | critical | moderate | non important | - |
| Nephritis TRAE (grade 3-4) | 1.79 [0.47, 6.87] | | < 1 | | 0% | 7 studies (7/-) | 19.9 % | some concern | serious | moderate | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.14 [0.06, 0.36] | | < 1 | | 84% | 11 studies (11/-) | 100.0 % | some concern | critical | moderate | non important | - |
| Pancreatitis TRAE (grade 3-4) | 1.73 [0.31, 9.58] | | < 1 | | 0% | 4 studies (4/-) | 26.5 % | some concern | not evaluable | moderate | non important | - |
| Pancytopenia TRAE (grade 3-4) | 0.52 [0.02, 15.84] | | < 1 | | 0% | 1 study (1/-) | 64.4 % | NA | not evaluable | | non important | - |
| Peripheral neuropathy TRAE (grade 3-4) | 0.98 [0.25, 3.89] | | < 1 | | 9% | 4 studies (4/-) | 51.1 % | some concern | not evaluable | moderate | non important | - |
| Peripheral oedema TRAE (grade 3-4) | 1.02 [0.06, 16.38] | | < 1 | | 0% | 2 studies (2/-) | 49.5 % | some concern | not evaluable | moderate | non important | - |
| Peripheral sensory neuropathy TRAE (grade 3-4) | 0.64 [0.01, 29.61] | | < 1 | | 78% | 2 studies (2/-) | 58.9 % | some concern | not evaluable | moderate | non important | - |
| Pneumonia TRAE (grade 3-4) | 2.12 [0.07, 64.42] | | < 1 | | 0% | 1 study (1/-) | 33.5 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 2.50 [1.33, 4.70] | | < 1 | | 0% | 10 studies (10/-) | 0.2 % | some concern | low | moderate | non important | - |
| Pruritus TRAE (grade 3-4) | 1.90 [0.64, 5.69] | | < 1 | | 0% | 10 studies (10/-) | 12.5 % | some concern | critical | moderate | non important | - |
| Pyrexia TRAE (grade 3-4) | 0.66 [0.05, 8.61] | | < 1 | | 0% | 2 studies (2/-) | 62.4 % | some concern | not evaluable | moderate | non important | - |
| Rash TRAE (grade 3-4) | 2.22 [1.08, 4.57] | | < 1 | | 0% | 13 studies (13/-) | 1.6 % | some concern | low | moderate | non important | - |
| Renal and urinary disorders TRAE (grade 3-4) | 1.97 [0.07, 59.09] | | < 1 | | 0% | 1 study (1/-) | 35.0 % | NA | not evaluable | | non important | - |
| Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) | 12.07 [0.67, 217.19] | | < 1 | | 0% | 1 study (1/-) | 4.7 % | NA | not evaluable | | non important | - |
| Sepsis TRAE (grade 3-4) | 2.12 [0.07, 64.42] | | < 1 | | 0% | 1 study (1/-) | 33.5 % | NA | not evaluable | | non important | - |
| Severe skin reaction TRAE (grade 3-4) | 2.45 [0.73, 8.21] | | < 1 | | 30% | 5 studies (5/-) | 7.3 % | some concern | not evaluable | moderate | non important | - |
| Skin and subcutaneous tissue disorders TRAE (grade 3-4) | 5.00 [0.58, 43.09] | | < 1 | | 0% | 1 study (1/-) | 7.3 % | NA | not evaluable | | non important | - |
| Stomatitis TRAE (grade 3-4) | 0.46 [0.08, 2.53] | | < 1 | | 0% | 4 studies (4/-) | 81.4 % | some concern | not evaluable | moderate | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 0.21 [0.07, 0.67] | | < 1 | | 76% | 8 studies (8/-) | 99.6 % | some concern | serious | moderate | non important | - |
| Thyroiditis TRAE (grade 3-4) | 0.78 [0.08, 7.49] | | < 1 | | 0% | 3 studies (3/-) | 58.6 % | some concern | not evaluable | moderate | non important | - |
| Vomiting TRAE (grade 3-4) | 0.46 [0.20, 1.06] | | < 1 | | 35% | 11 studies (11/-) | 96.5 % | some concern | low | moderate | non important | - |
AE (grade 3-4) endpoints 00 |
| hepatitis (Autoimmune) AE (grade 3-4) | 5.05 [0.55, 46.09] | | < 1 | | 0% | 2 studies (2/-) | 7.7 % | low | not evaluable | high | non important | - |
| Acute kidney injury AE (grade 3-4) | 0.24 [0.01, 5.34] | | < 1 | | 0% | 1 study (1/-) | 81.4 % | NA | not evaluable | | non important | - |
| Alopecia AE (grade 3-4) | 0.42 [0.09, 1.95] | | < 1 | | 0% | 4 studies (4/-) | 86.4 % | some concern | not evaluable | moderate | non important | - |
| Anaemia AE (grade 3-4) | 0.20 [0.08, 0.55] | | < 1 | | 92% | 6 studies (6/-) | 99.9 % | some concern | serious | moderate | non important | - |
| Arthralgia AE (grade 3-4) | 1.52 [0.33, 6.97] | | < 1 | | 0% | 2 studies (2/-) | 29.6 % | low | not evaluable | high | non important | - |
| Asthenia AE (grade 3-4) | 0.93 [0.61, 1.43] | | < 1 | | 0% | 6 studies (6/-) | 62.2 % | some concern | not evaluable | moderate | non important | - |
| Back pain AE (grade 3-4) | 0.48 [0.13, 1.77] | | < 1 | | 0% | 3 studies (3/-) | 86.3 % | some concern | not evaluable | moderate | non important | - |
| Blood creatinine increased AE (grade 3-4) | 0.48 [0.02, 14.38] | | < 1 | | 0% | 1 study (1/-) | 66.1 % | NA | not evaluable | | non important | - |
| Colitis AE (grade 3-4) | 2.04 [0.50, 8.23] | | < 1 | | 0% | 1 study (1/-) | 16.0 % | NA | not evaluable | | non important | - |
| Constipation AE (grade 3-4) | 1.21 [0.48, 3.01] | | < 1 | | 0% | 6 studies (6/-) | 34.5 % | some concern | not evaluable | moderate | non important | - |
| Cough AE (grade 3-4) | 0.90 [0.25, 3.23] | | < 1 | | 0% | 5 studies (5/-) | 56.4 % | low | not evaluable | high | non important | - |
| Decreased appetite AE (grade 3-4) | 1.49 [0.78, 2.85] | | < 1 | | 0% | 6 studies (6/-) | 11.3 % | some concern | not evaluable | moderate | non important | - |
| Diarrhoea AE (grade 3-4) | 1.08 [0.51, 2.29] | | < 1 | | 44% | 6 studies (6/-) | 42.0 % | some concern | serious | moderate | non important | - |
| Dyspnoea AE (grade 3-4) | 1.10 [0.66, 1.84] | | < 1 | | 0% | 6 studies (6/-) | 35.6 % | some concern | serious | moderate | non important | - |
| Epistaxis AE (grade 3-4) | 1.01 [0.02, 50.94] | | < 1 | | 0% | 1 study (1/-) | 49.9 % | NA | not evaluable | | non important | - |
| Fatigue AE (grade 3-4) | 1.10 [0.69, 1.75] | | < 1 | | 13% | 6 studies (6/-) | 34.9 % | some concern | not evaluable | moderate | non important | - |
